Biotechnology Group, Biological Sciences and Technology Division, CSIR-North East Institute of Science and Technology, Jorhat, 785006, Assam, India; Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India.
Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, 201002, India; Research Planning and Business Development Division, CSIR-North East Institute of Science and Technology, Jorhat, 785006, Assam, India.
Carbohydr Polym. 2020 Nov 1;247:116594. doi: 10.1016/j.carbpol.2020.116594. Epub 2020 Jun 18.
Chitosan, a promising carbohydrate biopolymer is gaining scientific attention in a wide range of biomedical applications due to its outstanding chemical and pharmacokinetic properties. Recently, various studies have demonstrated the beneficial activities of chitosan in protecting and proliferating pancreatic beta cells, lowering hyperglycemia, and preventing impaired lipid metabolism associated diabetes mellitus. Moreover, chitosan has also been used in formulating several types of micro/nano-carriers for the delivery of different antidiabetic drugs, like insulin, GLP1, exendin-4, DPP-4 inhibitor, and plasmid encoding insulin or GLP to reduce hyperglycemia. This review for the first time provides an overview of the currently available evidences on the potential benefits of chitosan in managing diabetes mellitus and also emphasizes on the chitosan-based micro/nano-carriers in delivery of various antidiabetic drugs via oral, nasal, and subcutaneous routes. The outcome of this review will be helpful for the development of a novel therapeutic to achieve better control of diabetes mellitus.
壳聚糖是一种有前途的碳水化合物生物聚合物，由于其出色的化学和药代动力学特性，在广泛的生物医学应用中引起了科学界的关注。最近，各种研究表明壳聚糖具有保护和增殖胰岛β细胞、降低高血糖和预防与糖尿病相关的脂质代谢受损的有益作用。此外，壳聚糖还被用于制备多种类型的微/纳米载体，用于输送不同的抗糖尿病药物，如胰岛素、GLP1、Exendin-4、DPP-4 抑制剂和编码胰岛素或 GLP 的质粒，以降低高血糖。这篇综述首次概述了壳聚糖在治疗糖尿病方面的潜在益处的现有证据，并强调了壳聚糖基微/纳米载体在通过口服、鼻内和皮下途径输送各种抗糖尿病药物方面的应用。这篇综述的结果将有助于开发新的治疗方法，以更好地控制糖尿病。
